SlidesetViral Hepatitis and Liver DiseaseStrategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)- Andrew Aronsohn, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseElimination of HCV: The DC Story- Henry Masur, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseEliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition- Anna S. Lok, MD, DScView Slideset
SlidesetViral Hepatitis and Liver DiseaseGlobal Strategies to Eliminate Hepatitis B (ICE-HBV)- Peter RevillView Slideset
SlidesetViral Hepatitis and Liver DiseaseEpidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study- Dr. M. RobertsonView Slideset
SlidesetViral Hepatitis and Liver DiseaseThe French and European Approach Towards Hepatitis Elimination- Tarik Asselah, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseNovel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (not available)- Dr. H. MitsuyaView Slideset
SlidesetViral Hepatitis and Liver DiseaseAccess to HIV, HBV, and HCV Antiviral Agents Globally- John Martin, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseDAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination- Jason GrebelyView Slideset
SlidesetViral Hepatitis and Liver DiseaseLiver Disease in Chinese-perspective from a Hepatologist- George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseA Tale of Two Viruses: HBV and HCV Co-infection (not available)- Jake LiangView Slideset
SlidesetViral Hepatitis and Liver DiseaseThe Global Burden of Non-alcoholic Steatohepatitis (not available)- Zobair YounossiView Slideset
SlidesetViral Hepatitis and Liver DiseaseShort Duration DAA HCV Therapy: How Short Can We Go?- Shyam Kottilil, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseElucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors (not available)- Dr. A. MatthewView Slideset
SlidesetViral Hepatitis and Liver DiseaseReal-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study (not yet available)- Dr. E. TamView Slideset
SlidesetViral Hepatitis and Liver DiseaseHepatitis B/C and NASH: Crossroads Between Science and Business (not available)- Geoffrey MeachamView Slideset
SlidesetViral Hepatitis and Liver DiseaseCatch me if you can – tuning immunity for HBV cure (not available)- Ulrike Protzer, MDView Slideset
SlidesetViral Hepatitis and Liver DiseasePersonalized Approaches to HBV Cure- Marion Peters, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimizing Infection Systems and Screens and Studying Innate anti-HBV Factors and Mechanisms- Lefteris Michailidis, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseIs Host Genome Integrated HBV Relevant? - The Con Perspective- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SlidesetViral Hepatitis and Liver DiseaseIs Host Genome Integrated HBV Relevant? - The Pro Perspective- Christian BrechotView Slideset
SlidesetViral Hepatitis and Liver DiseaseEndpoints and New Targets for Curing Hepatitis B- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SlidesetViral Hepatitis and Liver DiseaseCore Antibody: anti-HBc What is the Core of the Story?- Robert Gish, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseTargeting the HBV-Macrophage-Stellate cell axis to treat HBV-induced Liver Diseases- Lishan SuView Slideset
SlidesetViral Hepatitis and Liver DiseaseIn vivo evaluation of anti-HBV CRISPR/Cas9 therapy in the FRG mouse- Dr. K. JeromeView Slideset
SlidesetViral Hepatitis and Liver DiseaseDevelopment of Immune Competent Small Animal Models for HBV- Helene Strick-MarchandView Slideset
SlidesetViral Hepatitis and Liver DiseaseA novel immunotherapy for chronic HBV and HDV infections that bypass tolerance and induce broadly crossreactive and neutralizing antibodies (not available)- Dr. M. SallbergView Slideset
SlidesetViral Hepatitis and Liver DiseaseEmerging Therapeutic Targets and Concepts for Delta Hepatitis Virus (not yet available) - Jeffrey GlennView Slideset
SlidesetViral Hepatitis and Liver DiseaseRevisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination- Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEV Update: Diagnostics and Management- Kenneth Sherman, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseIs There a Best Host Acting Antiviral for HBV Cure?- Jake LiangView Slideset
SlidesetViral Hepatitis and Liver DiseaseIs there a best immunomodulator in development?- Ulrike ProtzerView Slideset
SlidesetViral Hepatitis and Liver DiseaseIs there a best Direct Acting Antiviral in development?- Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseNew directions towards functional cure of Chronic Hepatitis B- Lawrence Blatt, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseLooking back to move forward: designing next-gen RNAi for best results in HBV- Bruce GivenView Slideset
SlidesetViral Hepatitis and Liver DiseaseSB 9200: A novel RIG-I agonist for chronic hepatitis B- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
SlidesetViral Hepatitis and Liver DiseaseImmunotherapy is coming for HCC- Spiros Hiotis, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseStudies of the HBV-immune modulator AIC649 (not yet available)- Helga Rübsamen-schaeffView Slideset
SlidesetViral Hepatitis and Liver DiseaseControlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure- Michael Sofia, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseClinical Challenges in HCV infection- Mark Sulkowski, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseEliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)- Joseph Doyle, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseManagement of HCV in Decompensated liver disease- Michael MannsView Slideset
SlidesetViral Hepatitis and Liver DiseaseDAA Controversies: Do they Cause HBV Reactivation and/or HCC?- Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseasePan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination- Tarik AsselahView Slideset
SlidesetViral Hepatitis and Liver DiseaseWhen are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul PockrosView Slideset
SlidesetViral Hepatitis and Liver DiseaseLong term follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin in the AMBER – real world experience study- Dr. R. FlisiakView Slideset
SlidesetViral Hepatitis and Liver DiseaseA Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization- Dr. N. ManiView Slideset
SlidesetViral Hepatitis and Liver DiseaseNASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes- Arun SanyalView Slideset
SlidesetViral Hepatitis and Liver DiseasePredicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors- Dr. B. CoxView Slideset
SlidesetViral Hepatitis and Liver DiseaseEvolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside (not available)- Michael FriedView Slideset
SlidesetViral Hepatitis and Liver DiseaseSustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease (not available)- Dr. E. LawitzView Slideset
SlidesetViral Hepatitis and Liver DiseaseHigh Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study- Dr. A. AbergelView Slideset
SlidesetViral Hepatitis and Liver DiseaseThe Re-vival of Bile Acid Based Therapeutics for Children and Adults- Saul KarpenView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on Prophylactic HCV Vaccine Development- Andrea Cox, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHepatitis B virus splice variants are associated with and predictive of Liver cancer- Dr. P. RevillView Slideset
SlidesetViral Hepatitis and Liver DiseaseSeroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience- Dr. S. OnoView Slideset
SlidesetViral Hepatitis and Liver DiseaseLessons learned towards a Vaccine and Functional Cure for HIV (not available)- Mario StevensonView Slideset
SlidesetViral Hepatitis and Liver DiseaseLiver Directed Acetyl-CoA Carboxylase Inhibitor GS-0976 For NASH (not available)- Adrian RayView Slideset
SlidesetViral Hepatitis and Liver DiseaseThe Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations- Manal El-Sayed, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseAramchol for NASH and beyond: From scientific rationale to clinical development- Carol BrosgartView Slideset
SlidesetViral Hepatitis and Liver DiseaseRNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes- Dr. S. GhoshView Slideset
SlidesetViral Hepatitis and Liver DiseaseEvidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)- Dr. R. FosterView Slideset
SlidesetViral Hepatitis and Liver DiseaseTwo Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years- Dr. R. HyerView Slideset
SlidesetViral Hepatitis and Liver DiseaseAn Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells (not yet available)- Dr. E. ThomasView Slideset
SlidesetViral Hepatitis and Liver DiseaseValidation of a novel Transient Elastography for the measurement of liver fibrosis- Dr. J. DongView Slideset
SlidesetViral Hepatitis and Liver DiseaseEstablishment of functional control and normalization of liver function in HBeAg negative chronic HBV infection following combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a.- Dr. A. VaillantView Slideset
